Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).
Identifieur interne : 003409 ( Main/Exploration ); précédent : 003408; suivant : 003410Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).
Auteurs : Ian T. Meredith [Australie] ; Paul S. Teirstein [États-Unis] ; Alain Bouchard [États-Unis] ; Didier Carrié [France] ; Helge Möllmann [Allemagne] ; Keith G. Oldroyd [Royaume-Uni] ; Jack Hall [États-Unis] ; Dominic J. Allocco [États-Unis] ; Keith D. Dawkins [États-Unis] ; Gregg W. Stone [États-Unis]Source :
- The American journal of cardiology [ 1879-1913 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Alliages de chrome, Composés du platine, Conception de prothèse, Coronarographie, Endoprothèses à élution de substances, Facteurs temps, Femelle, Humains, Immunosuppresseurs (pharmacologie), Mâle, Méthode en double aveugle, Occlusion coronarienne (), Occlusion coronarienne (imagerie diagnostique), Occlusion coronarienne (mortalité), Revascularisation myocardique (), Résultat thérapeutique, Sirolimus (analogues et dérivés), Sirolimus (pharmacologie), Taux de survie (tendances), Études de suivi, Évérolimus.
- MESH :
- analogues et dérivés : Sirolimus.
- imagerie diagnostique : Occlusion coronarienne.
- mortalité : Occlusion coronarienne.
- pharmacologie : Immunosuppresseurs, Sirolimus.
- tendances : Taux de survie.
- Adulte d'âge moyen, Alliages de chrome, Composés du platine, Conception de prothèse, Coronarographie, Endoprothèses à élution de substances, Facteurs temps, Femelle, Humains, Mâle, Méthode en double aveugle, Occlusion coronarienne, Revascularisation myocardique, Résultat thérapeutique, Études de suivi, Évérolimus.
English descriptors
- KwdEn :
- Chromium Alloys, Coronary Angiography, Coronary Occlusion (diagnostic imaging), Coronary Occlusion (mortality), Coronary Occlusion (surgery), Double-Blind Method, Drug-Eluting Stents, Everolimus, Female, Follow-Up Studies, Humans, Immunosuppressive Agents (pharmacology), Male, Middle Aged, Myocardial Revascularization (methods), Platinum Compounds, Prosthesis Design, Sirolimus (analogs & derivatives), Sirolimus (pharmacology), Survival Rate (trends), Time Factors, Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : Sirolimus.
- chemical , pharmacology : Immunosuppressive Agents, Sirolimus.
- chemical : Chromium Alloys, Everolimus, Platinum Compounds.
- diagnostic imaging : Coronary Occlusion.
- methods : Myocardial Revascularization.
- mortality : Coronary Occlusion.
- surgery : Coronary Occlusion.
- trends : Survival Rate.
- Coronary Angiography, Double-Blind Method, Drug-Eluting Stents, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prosthesis Design, Time Factors, Treatment Outcome.
Abstract
In the randomized PLATINUM trial, the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES; Boston Scientific, Natick, Massachusetts) was noninferior to the XIENCE V cobalt-chromium everolimus-eluting stent (CoCr-EES; Boston Scientific and Abbott Vascular, Santa Clara, California) for the primary end point of 1-year target lesion failure. This study reports the 3-year outcomes. Patients (n=1,530) with 1 or 2 de novo native coronary artery lesions (baseline vessel diameter≥2.50 mm to ≤4.25 mm and length≤24 mm) were randomized 1:1 to PtCr-EES versus CoCr-EES. Three-year follow-up was available in 93.9% (703 of 749) of patients with CoCr-EES and 96.7% (733 of 758) of patients with PtCr-EES. Comparing CoCr-EES with PtCr-EES, 3-year rates of death (4.3% vs 3.7%, hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.52 to 1.48, p=0.62), cardiac death (1.9% vs 1.2%, HR 0.63, 95% CI 0.27 to 1.45, p=0.27), myocardial infarction (2.5% vs 2.3%, HR 0.92, 95% CI 0.48 to 1.79, p=0.81), ischemia-driven target lesion revascularization (4.9% vs 3.5%, HR 0.72, 95% CI 0.43 to 1.20, p=0.21), and Academic Research Consortium definite or probable stent thrombosis (0.5% vs 0.7%, HR 1.23, 95% CI 0.33 to 4.57, p=0.76) were not significantly different. In conclusion, 3-year results of the PLATINUM randomized, controlled, clinical trial demonstrate comparable safety and efficacy outcomes of the PROMUS Element PtCr-EES and the XIENCE V CoCr-EES.
DOI: 10.1016/j.amjcard.2013.12.011
PubMed: 24530167
Affiliations:
- Allemagne, Australie, France, Royaume-Uni, États-Unis
- Alabama, Californie, Indiana, Massachusetts, Midi-Pyrénées, Occitanie (région administrative), État de New York
- Toulouse
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003835
- to stream PubMed, to step Curation: 003721
- to stream PubMed, to step Checkpoint: 003721
- to stream Ncbi, to step Merge: 001787
- to stream Ncbi, to step Curation: 001787
- to stream Ncbi, to step Checkpoint: 001787
- to stream Main, to step Merge: 003421
- to stream Main, to step Curation: 003409
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).</title><author><name sortKey="Meredith, Ian T" sort="Meredith, Ian T" uniqKey="Meredith I" first="Ian T" last="Meredith">Ian T. Meredith</name><affiliation wicri:level="1"><nlm:affiliation>MonashHeart, Monash Health, Monash Medical Centre, Clayton, Victoria, Australia. Electronic address: ian.meredith@myheart.id.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>MonashHeart, Monash Health, Monash Medical Centre, Clayton, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Teirstein, Paul S" sort="Teirstein, Paul S" uniqKey="Teirstein P" first="Paul S" last="Teirstein">Paul S. Teirstein</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Division of Cardiovascular Diseases, Scripps Clinic, La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Bouchard, Alain" sort="Bouchard, Alain" uniqKey="Bouchard A" first="Alain" last="Bouchard">Alain Bouchard</name><affiliation wicri:level="2"><nlm:affiliation>Princeton Baptist Medical Center, Birmingham, Alabama.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Princeton Baptist Medical Center, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Carrie, Didier" sort="Carrie, Didier" uniqKey="Carrie D" first="Didier" last="Carrié">Didier Carrié</name><affiliation wicri:level="3"><nlm:affiliation>Cardiology Department, Centre Hospitalier Universitaire Rangueil, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Cardiology Department, Centre Hospitalier Universitaire Rangueil, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Mollmann, Helge" sort="Mollmann, Helge" uniqKey="Mollmann H" first="Helge" last="Möllmann">Helge Möllmann</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim</wicri:regionArea><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion></affiliation></author><author><name sortKey="Oldroyd, Keith G" sort="Oldroyd, Keith G" uniqKey="Oldroyd K" first="Keith G" last="Oldroyd">Keith G. Oldroyd</name><affiliation wicri:level="1"><nlm:affiliation>West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Clydebank, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Clydebank</wicri:regionArea><wicri:noRegion>Clydebank</wicri:noRegion></affiliation></author><author><name sortKey="Hall, Jack" sort="Hall, Jack" uniqKey="Hall J" first="Jack" last="Hall">Jack Hall</name><affiliation wicri:level="2"><nlm:affiliation>The Heart Center, St. Vincent's Hospital, Indianapolis, Indiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Indiana</region></placeName><wicri:cityArea>The Heart Center, St. Vincent's Hospital, Indianapolis</wicri:cityArea></affiliation></author><author><name sortKey="Allocco, Dominic J" sort="Allocco, Dominic J" uniqKey="Allocco D" first="Dominic J" last="Allocco">Dominic J. Allocco</name><affiliation wicri:level="2"><nlm:affiliation>Boston Scientific Corporation, Natick, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston Scientific Corporation, Natick</wicri:cityArea></affiliation></author><author><name sortKey="Dawkins, Keith D" sort="Dawkins, Keith D" uniqKey="Dawkins K" first="Keith D" last="Dawkins">Keith D. Dawkins</name><affiliation wicri:level="2"><nlm:affiliation>Boston Scientific Corporation, Natick, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston Scientific Corporation, Natick</wicri:cityArea></affiliation></author><author><name sortKey="Stone, Gregg W" sort="Stone, Gregg W" uniqKey="Stone G" first="Gregg W" last="Stone">Gregg W. Stone</name><affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Research Foundation, Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Cardiovascular Research Foundation, Columbia University Medical Center/New York-Presbyterian Hospital, New York</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24530167</idno><idno type="pmid">24530167</idno><idno type="doi">10.1016/j.amjcard.2013.12.011</idno><idno type="wicri:Area/PubMed/Corpus">003835</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003835</idno><idno type="wicri:Area/PubMed/Curation">003721</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003721</idno><idno type="wicri:Area/PubMed/Checkpoint">003721</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003721</idno><idno type="wicri:Area/Ncbi/Merge">001787</idno><idno type="wicri:Area/Ncbi/Curation">001787</idno><idno type="wicri:Area/Ncbi/Checkpoint">001787</idno><idno type="wicri:Area/Main/Merge">003421</idno><idno type="wicri:Area/Main/Curation">003409</idno><idno type="wicri:Area/Main/Exploration">003409</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).</title><author><name sortKey="Meredith, Ian T" sort="Meredith, Ian T" uniqKey="Meredith I" first="Ian T" last="Meredith">Ian T. Meredith</name><affiliation wicri:level="1"><nlm:affiliation>MonashHeart, Monash Health, Monash Medical Centre, Clayton, Victoria, Australia. Electronic address: ian.meredith@myheart.id.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>MonashHeart, Monash Health, Monash Medical Centre, Clayton, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Teirstein, Paul S" sort="Teirstein, Paul S" uniqKey="Teirstein P" first="Paul S" last="Teirstein">Paul S. Teirstein</name><affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Division of Cardiovascular Diseases, Scripps Clinic, La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Bouchard, Alain" sort="Bouchard, Alain" uniqKey="Bouchard A" first="Alain" last="Bouchard">Alain Bouchard</name><affiliation wicri:level="2"><nlm:affiliation>Princeton Baptist Medical Center, Birmingham, Alabama.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Princeton Baptist Medical Center, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Carrie, Didier" sort="Carrie, Didier" uniqKey="Carrie D" first="Didier" last="Carrié">Didier Carrié</name><affiliation wicri:level="3"><nlm:affiliation>Cardiology Department, Centre Hospitalier Universitaire Rangueil, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Cardiology Department, Centre Hospitalier Universitaire Rangueil, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Mollmann, Helge" sort="Mollmann, Helge" uniqKey="Mollmann H" first="Helge" last="Möllmann">Helge Möllmann</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim</wicri:regionArea><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion></affiliation></author><author><name sortKey="Oldroyd, Keith G" sort="Oldroyd, Keith G" uniqKey="Oldroyd K" first="Keith G" last="Oldroyd">Keith G. Oldroyd</name><affiliation wicri:level="1"><nlm:affiliation>West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Clydebank, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Clydebank</wicri:regionArea><wicri:noRegion>Clydebank</wicri:noRegion></affiliation></author><author><name sortKey="Hall, Jack" sort="Hall, Jack" uniqKey="Hall J" first="Jack" last="Hall">Jack Hall</name><affiliation wicri:level="2"><nlm:affiliation>The Heart Center, St. Vincent's Hospital, Indianapolis, Indiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Indiana</region></placeName><wicri:cityArea>The Heart Center, St. Vincent's Hospital, Indianapolis</wicri:cityArea></affiliation></author><author><name sortKey="Allocco, Dominic J" sort="Allocco, Dominic J" uniqKey="Allocco D" first="Dominic J" last="Allocco">Dominic J. Allocco</name><affiliation wicri:level="2"><nlm:affiliation>Boston Scientific Corporation, Natick, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston Scientific Corporation, Natick</wicri:cityArea></affiliation></author><author><name sortKey="Dawkins, Keith D" sort="Dawkins, Keith D" uniqKey="Dawkins K" first="Keith D" last="Dawkins">Keith D. Dawkins</name><affiliation wicri:level="2"><nlm:affiliation>Boston Scientific Corporation, Natick, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston Scientific Corporation, Natick</wicri:cityArea></affiliation></author><author><name sortKey="Stone, Gregg W" sort="Stone, Gregg W" uniqKey="Stone G" first="Gregg W" last="Stone">Gregg W. Stone</name><affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Research Foundation, Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Cardiovascular Research Foundation, Columbia University Medical Center/New York-Presbyterian Hospital, New York</wicri:cityArea></affiliation></author></analytic><series><title level="j">The American journal of cardiology</title><idno type="eISSN">1879-1913</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chromium Alloys</term><term>Coronary Angiography</term><term>Coronary Occlusion (diagnostic imaging)</term><term>Coronary Occlusion (mortality)</term><term>Coronary Occlusion (surgery)</term><term>Double-Blind Method</term><term>Drug-Eluting Stents</term><term>Everolimus</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Immunosuppressive Agents (pharmacology)</term><term>Male</term><term>Middle Aged</term><term>Myocardial Revascularization (methods)</term><term>Platinum Compounds</term><term>Prosthesis Design</term><term>Sirolimus (analogs & derivatives)</term><term>Sirolimus (pharmacology)</term><term>Survival Rate (trends)</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Alliages de chrome</term><term>Composés du platine</term><term>Conception de prothèse</term><term>Coronarographie</term><term>Endoprothèses à élution de substances</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Immunosuppresseurs (pharmacologie)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Occlusion coronarienne ()</term><term>Occlusion coronarienne (imagerie diagnostique)</term><term>Occlusion coronarienne (mortalité)</term><term>Revascularisation myocardique ()</term><term>Résultat thérapeutique</term><term>Sirolimus (analogues et dérivés)</term><term>Sirolimus (pharmacologie)</term><term>Taux de survie (tendances)</term><term>Études de suivi</term><term>Évérolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Immunosuppressive Agents</term><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Chromium Alloys</term><term>Everolimus</term><term>Platinum Compounds</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Coronary Occlusion</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Occlusion coronarienne</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Myocardial Revascularization</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronary Occlusion</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Occlusion coronarienne</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Immunosuppresseurs</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Coronary Occlusion</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Taux de survie</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Coronary Angiography</term><term>Double-Blind Method</term><term>Drug-Eluting Stents</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prosthesis Design</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Alliages de chrome</term><term>Composés du platine</term><term>Conception de prothèse</term><term>Coronarographie</term><term>Endoprothèses à élution de substances</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Occlusion coronarienne</term><term>Revascularisation myocardique</term><term>Résultat thérapeutique</term><term>Études de suivi</term><term>Évérolimus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the randomized PLATINUM trial, the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES; Boston Scientific, Natick, Massachusetts) was noninferior to the XIENCE V cobalt-chromium everolimus-eluting stent (CoCr-EES; Boston Scientific and Abbott Vascular, Santa Clara, California) for the primary end point of 1-year target lesion failure. This study reports the 3-year outcomes. Patients (n=1,530) with 1 or 2 de novo native coronary artery lesions (baseline vessel diameter≥2.50 mm to ≤4.25 mm and length≤24 mm) were randomized 1:1 to PtCr-EES versus CoCr-EES. Three-year follow-up was available in 93.9% (703 of 749) of patients with CoCr-EES and 96.7% (733 of 758) of patients with PtCr-EES. Comparing CoCr-EES with PtCr-EES, 3-year rates of death (4.3% vs 3.7%, hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.52 to 1.48, p=0.62), cardiac death (1.9% vs 1.2%, HR 0.63, 95% CI 0.27 to 1.45, p=0.27), myocardial infarction (2.5% vs 2.3%, HR 0.92, 95% CI 0.48 to 1.79, p=0.81), ischemia-driven target lesion revascularization (4.9% vs 3.5%, HR 0.72, 95% CI 0.43 to 1.20, p=0.21), and Academic Research Consortium definite or probable stent thrombosis (0.5% vs 0.7%, HR 1.23, 95% CI 0.33 to 4.57, p=0.76) were not significantly different. In conclusion, 3-year results of the PLATINUM randomized, controlled, clinical trial demonstrate comparable safety and efficacy outcomes of the PROMUS Element PtCr-EES and the XIENCE V CoCr-EES.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Alabama</li><li>Californie</li><li>Indiana</li><li>Massachusetts</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>État de New York</li></region><settlement><li>Toulouse</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Meredith, Ian T" sort="Meredith, Ian T" uniqKey="Meredith I" first="Ian T" last="Meredith">Ian T. Meredith</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="Teirstein, Paul S" sort="Teirstein, Paul S" uniqKey="Teirstein P" first="Paul S" last="Teirstein">Paul S. Teirstein</name></region><name sortKey="Allocco, Dominic J" sort="Allocco, Dominic J" uniqKey="Allocco D" first="Dominic J" last="Allocco">Dominic J. Allocco</name><name sortKey="Bouchard, Alain" sort="Bouchard, Alain" uniqKey="Bouchard A" first="Alain" last="Bouchard">Alain Bouchard</name><name sortKey="Dawkins, Keith D" sort="Dawkins, Keith D" uniqKey="Dawkins K" first="Keith D" last="Dawkins">Keith D. Dawkins</name><name sortKey="Hall, Jack" sort="Hall, Jack" uniqKey="Hall J" first="Jack" last="Hall">Jack Hall</name><name sortKey="Stone, Gregg W" sort="Stone, Gregg W" uniqKey="Stone G" first="Gregg W" last="Stone">Gregg W. Stone</name></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Carrie, Didier" sort="Carrie, Didier" uniqKey="Carrie D" first="Didier" last="Carrié">Didier Carrié</name></region></country><country name="Allemagne"><noRegion><name sortKey="Mollmann, Helge" sort="Mollmann, Helge" uniqKey="Mollmann H" first="Helge" last="Möllmann">Helge Möllmann</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Oldroyd, Keith G" sort="Oldroyd, Keith G" uniqKey="Oldroyd K" first="Keith G" last="Oldroyd">Keith G. Oldroyd</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003409 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003409 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24530167
|texte= Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24530167" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |